健康元药业集团 关于提供担保进展情况的公告 证券代码：600380 证券简称：健康元 公告编号：临 2024-043 健康元药业集团股份有限公司 关于提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●2024 年 4 月，健康元药业集团股份有限公司（以下简称：本公司）控股子公司 丽珠医药集团股份有限公司（以下简称：丽珠集团）与交通银行股份有限公司珠海分行 （以下简称：交通银行）签署担保协议，被担保人为丽珠集团新北江制药股份有限公司 （以下简称：新北江制药），担保金额为人民币 4,000 万元；丽珠集团与广发银行股份 有限公司珠海分行（以下简称：广发银行）签署担保协议，被担保人为珠海保税区丽珠 合成制药有限公司（以下简称：丽珠合成），担保金额为人民币 15,000 万元；丽珠集团 与招商银行股份有限公司珠海分行（以下简称：招商银行）签署担保协议，被担保人为 丽珠集团丽珠制药厂（以下简称：丽珠制药厂），担保金额为人民币 20,000 万元。 ●被担保人均为丽珠集团全资或控股子公司，不存在关联担 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1][2] - The target price is set at 15.12 CNY, up from the previous forecast of 13.68 CNY [1][2] Core Insights - The company's performance meets expectations, with a gradual increase in the volume of the drug Tobramycin anticipated [1] - The respiratory segment is expected to show positive growth, particularly with the approval of a new product, which will contribute to revenue [1] - The report highlights the potential for Tobramycin to offset revenue declines caused by price reductions in other products [1] Financial Summary - For Q1 2024, the company reported a net profit attributable to shareholders of 1.44 billion CNY, a decrease of 4% year-on-year [1] - The revenue for Q1 2024 is projected at 4.34 billion CNY, reflecting a decline of 4.8% [1] - The earnings per share (EPS) forecast for 2024 is 0.84 CNY, with subsequent years showing an upward trend [1][2] Market Position - The total market capitalization of the company is 22.4 billion CNY [2] - The stock has a 52-week price range of 10.43 to 13.86 CNY [2] - The company operates in the pharmaceutical sector, focusing on a diverse range of products including chemical formulations and traditional Chinese medicine [2]

健康元药业集团 关于公司药品注射用醋酸西曲瑞克获得美国 FDA 批准的公告 证券代码：600380 证券简称：健康元 公告编号：临 2024-042 健康元药业集团股份有限公司 关于公司药品注射用醋酸西曲瑞克获得美国 FDA 批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，健康元药业集团股份有限公司（以下简称：本公司）的控股子公司丽 珠医药集团股份有限公司（以下简称：丽珠集团）全资子公司丽珠集团丽珠制药 厂收到美国食品药品监督管理局（以下简称：美国 FDA）签发的 ANDA 批准通 知（ANDA 号：214540），批准丽珠集团研发的注射用醋酸西曲瑞克在美国上市 销售。现将相关情况公告如下： 一、药品的基本情况 规格：0.25mg/瓶 ANDA 号：214540 药品有效期：24 个月 申请人：丽珠集团丽珠制药厂 生产企业：南京健友生化制药股份有限公司 二、药品其他相关情况 注射用醋酸西曲瑞克是第三代促性腺激素释放激素拮抗剂（gonadotropin- releasing hormone antagonist ...

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company's Q1 2024 performance met expectations, with revenue of 4.34 billion and net profit of 440 million, both showing slight year-on-year declines of 4.81% and 4.96% respectively. The decline is attributed to price reductions from the ninth batch of centralized procurement for a specific inhalation solution. However, the company anticipates a gradual increase in sales volume of Tobramycin and other products throughout 2024, leading to improved performance [1][2]. Summary by Sections Financial Performance - In Q1 2024, the company reported a revenue of 4.34 billion, a year-on-year decrease of 4.81%. The net profit was 440 million, down 4.96% year-on-year. The adjusted net profit was 428 million, reflecting a decline of 4.26% [1]. - The sales expense ratio decreased to 25.29% from 26.77% in Q1 2023, while the R&D expense ratio increased to 8.69% from 8.36% [2]. - The company achieved a significant increase in operating cash flow, which grew by 291.91% year-on-year [2]. Segment Performance - Chemical preparations generated revenue of 2.14 billion, down 4.86% year-on-year. Hormonal products saw a revenue increase of 39.89% to 807 million, while gastrointestinal products decreased by 25.68% to 589 million [2]. - The revenue from raw materials and intermediates was 1.40 billion, down 3.70% year-on-year. Traditional Chinese medicine revenue fell by 28.38% to 406 million [2]. - Diagnostic reagents and equipment revenue surged by 60.26% to 236 million, and health products saw a remarkable growth of 96.50% to 78 million [2]. Future Outlook - The company is focusing on expanding its respiratory product line, with Tobramycin expected to gain market share following its inclusion in medical insurance. The company anticipates that the product will see rapid growth in 2024 [2]. - The company is also advancing its pipeline in various disease areas, with several innovative products in clinical trials, including an anti-influenza drug expected to be submitted for approval in Q3 2024 [2]. Profit Forecast - The company is projected to achieve net profits of 1.56 billion, 1.75 billion, and 1.99 billion for 2024, 2025, and 2026 respectively, with growth rates of 8.4%, 12.1%, and 13.6% [3].

健康元药业集团 使用信用证支付募投项目资金的公告 证券代码：600380 证券简称： 健康元 公告编号：临 2024-040 健康元药业集团股份有限公司关于使用 信用证支付募投项目资金并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）于 2024 年 4 月 25 日召 开八届董事会三十九次会议，审议并通过《关于使用信用证支付募投项目资金并以 募集资金等额置换的议案》，同意公司在募集资金投资项目实施期间，使用信用证 支付募集资金投资项目中涉及的款项，并定期从募集资金专项账户中等额置换转入 公司一般账户。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称：中国证监会）核发的《关于核准健康 元药业集团股份有限公司配股的批复》（证监许可[2018]1284 号）批准，公司向原 股东配售 365,105,066 股新股。本次配股计划募集资金 200,000.00 万元，实际募集 资金总额为 171,599.38 万元，扣除发行费用 4 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 4,339,814,452.16, a decrease of 4.81% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 439,798,106.55, down 4.96% year-on-year[4] - The revenue from chemical preparations was CNY 2,141 million, a decline of 4.86% year-on-year, with hormone products showing a growth of 39.89% to CNY 807 million[5] - The company reported a significant increase in revenue from diagnostic reagents and equipment, which rose by 60.26% to CNY 236 million[5] - The company’s basic earnings per share for Q1 2024 were CNY 0.2357, a decrease of 1.96% year-on-year[4] - The company’s weighted average return on equity decreased by 0.34 percentage points to 3.15%[4] - Total operating revenue for Q1 2024 was approximately ¥4.34 billion, a decrease of 4.8% compared to ¥4.56 billion in Q1 2023[18] - Net profit for Q1 2024 reached approximately ¥925.1 million, an increase of 5.3% from ¥878.5 million in Q1 2023[18] - Operating profit for Q1 2024 was approximately ¥1.09 billion, up from ¥1.05 billion in Q1 2023, reflecting a growth of 4.0%[18] - Total comprehensive income for Q1 2024 was approximately ¥902.6 million, compared to ¥794.8 million in Q1 2023, indicating an increase of 13.6%[19] - Basic earnings per share for Q1 2024 were ¥0.2357, slightly down from ¥0.2404 in Q1 2023[19] - The total operating costs for Q1 2024 were approximately ¥3.30 billion, down from ¥3.56 billion in Q1 2023, reflecting a decrease of 7.5%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 291.91% to CNY 972,276,972.65, primarily due to reduced procurement and expense expenditures[7] - Cash flow from operating activities for Q1 2024 was approximately ¥972.3 million, significantly higher than ¥248.1 million in Q1 2023[20] - Current assets totaled RMB 23,443,751,168.49, down from RMB 23,874,630,390.40 at the end of 2023, primarily due to a decrease in cash and cash equivalents[16] - The company's cash and cash equivalents decreased to RMB 15,118,198,045.39 from RMB 15,691,888,314.83, reflecting a decline of approximately 3.65%[16] - Accounts receivable increased to RMB 2,641,495,146.49 from RMB 2,692,941,866.24, indicating a slight rise in receivables[16] - Total assets at the end of Q1 2024 were CNY 36,462,147,240.89, reflecting a slight increase of 0.29% from the end of the previous year[4] - The non-current assets increased to RMB 13,018,396,072.40 from RMB 12,483,495,868.42, reflecting a growth of approximately 4.29%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 78,332[11] - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., holds 895,653,653 shares, accounting for 47.98% of the total shares[11] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 87,780,030 shares, representing 4.70%[11] - The company reported a total of 9,370,400 shares under the third phase of the long-term partner shareholding plan[12] - The shareholding structure indicates no related party relationships among the top shareholders[12] - The top 10 shareholders collectively hold a significant portion of the shares, with the largest shareholder alone holding nearly half[11] - The company has not reported any significant changes in the shareholding structure due to margin trading activities[13] - The total shares held by the China Agricultural Bank's CSI 500 ETF amounted to 10,353,414, representing 0.55% of the total shares[13] Liabilities and Equity - Total liabilities decreased to RMB 12,925,489,486.86 from RMB 13,718,595,768.18, showing a reduction of approximately 5.78%[17] - The company's equity attributable to shareholders rose to RMB 14,234,869,509.55 from RMB 13,755,901,924.06, an increase of about 3.48%[17] - Short-term borrowings decreased significantly to RMB 1,360,009,625.00 from RMB 2,076,159,347.22, a reduction of approximately 34.5%[17] - The company reported a decrease in current liabilities, totaling RMB 9,865,306,342.16 compared to RMB 9,860,687,845.52 at the end of 2023[17] - The company’s retained earnings increased to RMB 9,878,656,063.35 from RMB 9,441,857,956.80, indicating a growth of about 4.64%[17] Audit and Reporting - The report does not indicate any significant operational issues during the reporting period[15] - There were no audit opinion types applicable for the quarterly financial statements[15] - Health元药业集团将于2024年首次执行新会计准则[22] - 2024年第一季度财务报表未涉及调整[22] - 健康元药业集团于2024年4月25日发布财报[22] - 2024年第一季度报告包含12页内容[22] - 报告未提及具体业绩数据和用户数据[22] - 未来展望和业绩指引未在报告中详细说明[22] - 新产品和新技术研发的相关信息未披露[22] - 市场扩张和并购策略未在报告中提及[22] - 其他新策略的具体内容未被列出[22] - 报告未提供具体的财务指标和百分比[22]

健康元药业集团 委托贷款公告 证券代码：600380 证券简称：健康元 公告编号：临 2024-038 健康元药业集团股份有限公司 ●委托贷款对象：健康元药业集团股份有限公司（以下简称：本公司）控股子 公司焦作健风生物科技有限公司（以下简称：焦作健风） ●委托贷款金额：10,000万元 ●委托贷款期限及利率：贷款期限为五年；浮动利率，根据中国人民银行公布 一年期贷款市场报价利率(LPR)+65BP。 ●是否需要提交公司股东大会审议：否 一、委托贷款概述 为满足控股子公司焦作健风前期项目建设及流动资金需求，本公司拟为其提供 期限为五年，总金额为人民币10,000万元的委托贷款，贷款利率为浮动利率，根据中 国人民银行公布的一年期贷款市场报价利率(LPR)+65BP。同时本次委托贷款由焦作 健风另外股东风火轮(上海)生物科技有限公司以其所持有的焦作健风股权作为担保。 2024 年 4 月 25 日，本公司召开八届董事会三十九次会议，审议并通过《关于本 公司向控股子公司焦作健风提供委托贷款的议案》，同意本公司向控股子公司焦作健 风因前期项目建设及流动资金需求提供期限五年，总金额为人民币 10,000 万元的委 托贷款 ...

健康元药业集团 关于聘任公司高级管理人员的公告 健康元药业集团股份有限公司 关于聘任公司高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）于2024年4月25日召开八 届董事会三十九次会议，审议并通过《关于任命林楠棋先生为本公司常务副总裁的 议案》及《关于任命幸志伟先生为本公司副总裁的议案》，现将相关情况公告如下： 二、聘任幸志伟先生为公司副总裁 为规范及提升本公司生产管理水平，为公司长远战略发展提供强有力的支持 和保障，经公司总裁提名，董事会提名委员会任职资格审查通过，董事会审议同意 任命幸志伟先生为本公司副总裁，负责本公司生产管理，任期自本次董事会表决通 过之日起至本公司八届董事会任期届满之日。 证券代码：600380 证券简称：健康元 公告编号：临 2024-036 一、聘任林楠棋先生为公司常务副总裁 为规范及提升本公司治理水平，为本公司长远战略发展提供强有力的支持和 保障，经公司总裁提名，董事会提名委员会任职资格审查通过，董事会审议同意任 命林楠棋先生为本 ...

健康元药业集团 八届董事会三十九次会议决议公告 证券代码：600380 证券简称：健康元 公告编号：临 2024-035 健康元药业集团股份有限公司 八届董事会三十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）八届董事会三十九次会议于2024 年4月16日（星期二）以电子邮件并电话确认的形式发出会议通知，并于2024年4月25日 （星期四）下午15:00在深圳市南山区高新区北区朗山路17号健康元药业集团大厦二号会 议室以现场加视频会议方式召开。会议应参加董事九人，实际参加董事九人，公司三名 监事会成员及公司总裁等高级管理人员列席了会议，符合《公司法》及《公司章程》的 规定。会议审议并通过如下议案： 一、审议并通过《关于任命林楠棋先生为本公司常务副总裁的议案》 为规范及提升本公司治理水平，为本公司长远战略发展提供强有力的支持和保障， 经公司总裁提名，董事会提名委员会审议，同意任命林楠棋先生为本公司常务副总裁， 负责公司国际业务及科研等相关工作，助力公司向国际化创新 ...

健康元药业集团 监事会审核意见 健康元药业集团股份有限公司 关于公司八届监事会三十一次会议相关议案之审核意见 本公司监事会认为：本公司 2024 年第一季度报告的编制和审议程序符合相关法 律法规、《公司章程》和公司内部管理制度的各项规定，第一季度报告的内容和格式 符合中国证监会和上海证券交易所的各项规定，所包含的信息能够从各方面真实、完 整地反映公司 2024 年第一季度的经营管理及财务状况，参与第一季度报告编制和审 议的人员均无违反保密规定的行为。 健康元药业集团股份有限公司 一、关于注销 2022 年股票期权激励计划部分股票期权之审核意见 本公司监事会认为：公司本次注销部分股票期权符合有关法律法规及公司《2022 年股票期权激励计划（草案）》的相关规定，不存在损害股东利益的情况，同意公司 此次注销部分股票期权。 二、关于使用信用证支付募投项目资金并以募集资金等额置换之审核意见 本公司监事会认为：公司使用信用证支付募投项目资金并以募集资金等额置换， 有利于节约财务费用，提高募集资金使用效率，改进募投项目款项支付方式。本次议 案的审议程序符合相关法律、法规、规范性文件及《公司章程》等有关规定，对公司 及全体股 ...